{"organizations": [], "uuid": "b8eb531c7389be1275b9b10113d9cf781074f9f0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 6, "shares": 6, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/11/10/104835933-GettyImages-118788349.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/10000664/device/rss/rss.html", "section_title": "Finance", "url": "https://www.cnbc.com/2018/03/26/after-hours-buzz-rht-anab-more.html", "country": "US", "domain_rank": 767, "title": "After-hours buzz: RHT, ANAB & more", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T01:34:00.000+03:00", "replies_count": 0, "uuid": "b8eb531c7389be1275b9b10113d9cf781074f9f0"}, "author": "Ingrid Angulo", "url": "https://www.cnbc.com/2018/03/26/after-hours-buzz-rht-anab-more.html", "ord_in_thread": 0, "title": "After-hours buzz: RHT, ANAB & more", "locations": [], "entities": {"persons": [{"name": "aimmune", "sentiment": "none"}, {"name": "anapstysbio", "sentiment": "none"}], "locations": [{"name": "powder river basin", "sentiment": "none"}], "organizations": [{"name": "sm energy", "sentiment": "none"}, {"name": "aimmune therapeutics", "sentiment": "none"}, {"name": "anaptysbio", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Check out the companies making headlines after the bell :\nShares of Red Hat surged nearly 5 percent after hours after the open-source software company reported its fourth-quarter earnings. The company reported earnings per share and revenue that beat Wall Street expectations. Sales rose 23 percent year over year to $772 million in the fourth quarter.\nAnaptysBio shares rallied over 12 percent post-market. The drug developer announced positive peanut allergy treatment data on Monday afternoon. Analysis of the mid-stage trial data pointed to nearly half of patients treated showing peanut tolerance.\nFollowing AnapstysBio's good news, shares of Aimmune Therapeutics fell nearly 2 percent. Aimmune's drug to treat peanut allergy in children succeeded in a late-stage study in February.\nSM Energy stock gained over 2 percent in extended trading. The natural gas exploration company announced that it completed a previously announced sale of the majority of its assets in the Powder River Basin for $500 million. The company plans to use the proceeds for general corporate purposes, including debt reduction.", "external_links": [], "published": "2018-03-27T01:34:00.000+03:00", "crawled": "2018-03-27T01:31:40.009+03:00", "highlightTitle": ""}